Managed to get my allocation on application. Very happy with the outcome.
Looking forward to seeing how the Noxopharm plan progresses. Key points for me are:
> NOX66 is a novel formulation of an effective compound - idronoxil
> Broad application across a range of cancers
> Trials in Eastern Europe is lower cost, the process quicker and apparently the ‘quality’ of patients is better since this may be their first treatment instead of last
> GK experienced at Human Trials and bringing drugs to market
All thumbs up for me plus a low enterprise value mean a strong investment opportunity I think. Let’s see if we start getting some good news in 2016 to set us up for a strong 2017
GLTA
Managed to get my allocation on application. Very happy with the...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
-0.006(7.69%) |
Mkt cap ! $21.04M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 8.0¢ | 7.2¢ | $52.57K | 665.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 6221 | 2 |
View Market Depth
| Last trade - 15.56pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.9¢ |
Change
-0.006 ( 5.33 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 23246 | ||
| Last updated 14.13pm 17/05/2024 ? | |||||
| NOX (ASX) Chart |